Author:
Vieito María,Gardeazabal Itziar,Matos Ignacio,Garralda Elena
Publisher
Springer International Publishing
Reference69 articles.
1. Kelloff GJ, Bast RC, Coffey DS, D’Amico AV, Kerbel RS, Park JW, et al. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res. 2004 Jun;10(11):3881–4.
2. Gainor JF, Longo DL, Chabner BA. Pharmacodynamic biomarkers: Falling short of the mark? Clin Cancer Res [Internet]. 2014 [cited 2018 Aug 29];20(10):2587–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24831281
3. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
4. National Cancer Institute. Pharmacodynamic Biomarkers | Development | NExT Resources | NExT [Internet]. [cited 2019 Jun 3]. Available from: https://next.cancer.gov/developmentResources/pd_biomarker.htm
5. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg. 2004;78(6):1903–9. discussion 1909